by van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Lancet Infect Dis, 2010, 10:184–94.
Summary: Combination therapy for the treatment of visceral leishmaniasis has increasingly been advocated as a way to increase treatment efficacy and tolerance, reduce treatment duration and cost, and limit the emergence of drug resistance. The authors reviewed the evidence and potential for combination therapy, and the criteria for the choice of drugs in such regimens.
